JPMORGAN CHASE & CO - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H203. A total of 20 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2022$026
-93.3%
0.00%
Q2 2022$0387
+14.8%
0.00%
Q1 2022$0337
+1148.1%
0.00%
Q4 2021$0
-100.0%
27
-99.7%
0.00%
Q2 2021$53,0009,129
+26750.0%
0.00%
Q1 2021$0340.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q3 2022
NameSharesValueWeighting ↓
Samjo Capital LLC 381,713$1,828,0001.56%
Cowen Prime Services LLC 441,918$2,117,0000.94%
Nantahala Capital Management 363,622$1,742,0000.05%
GSA CAPITAL PARTNERS LLP 45,221$217,0000.04%
HighMark Wealth Management LLC 6,666$32,0000.03%
Tower Research Capital LLC (TRC) 10,572$51,0000.00%
Qube Research & Technologies Ltd 12,034$58,0000.00%
Squarepoint Ops LLC 25,597$123,0000.00%
Ironwood Financial, llc 103$00.00%
OSAIC HOLDINGS, INC. 24$00.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders